Tag: japanese biosimilar market

Samsung Bioepis has made a significant move by partnering with NIPRO Corporation to commercialize biosimilars in Japan. The agreement includes the development and commercialization of multiple biosimilar candidates, such as SB17, an ustekinumab biosimilar candidate. The Big Book of Dashboards: Visualizing Your Data Using Real-World Business Scenarios | $49.19 As part of the deal, Samsung…